fda semaglutide The FDA's Decision to Ban Compounds: What You Need to Know FDA warns consumers not to

GLP-1 Receptor Agonists Could Reduce Risk of Glaucoma in Type 2 Diabetes Julia Bonavitacola Key Takeaways GLP-1 receptor agonists may reduce glaucoma risk in T2D patients, though the reduction was nonsignificant

Its a combination of things

However, emerging evidence suggests a potential link between GLP-1 therapy and altered pain perception, possibly through several mechanisms: 1- Neuroinflammation and Microglial Activation: GLP-1 receptors are expressed in the brainstem, spinal cord, and dorsal root ganglia, regions involved in pain modulation

A 6-month study of Rybelsus found an average drop of 1 to 1.3% A1C in adults with a starting A1C of 8.3%

Vitamin D status of children with severe early childhood caries: a case-control study

doi:10.1016/j.clim.2020.108544 76